Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gemoscan was a healthcare company specializing in food intolerance management and dietary wellness solutions. Headquartered in Toronto, the company developed and commercialized the HEMOCODE System, a proprietary blood-based diagnostic tool used to identify food sensitivities and provide personalized nutritional guidance. Gemoscan also operated a network of multidisciplinary paramedical clinics and established partnerships with major retail pharmacies to distribute its services across Canada and the United States. Its programs were designed as adjuncts to conventional medical practices, focusing on improving patient well-being through lifestyle and dietary modifications. The company ceased operations and filed for bankruptcy in early 2016 due to financial difficulties.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gemoscan International.